Pharmafile Logo
Pharmafocus logo
Advanced Search

Tremfya

Showing 12 posts of 12 posts found.

Janssen sign

Johnson & Johnson’s arthritis drug shows promising results in Phase III trial

March 16, 2021
Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

News
janssen_latest_logo_on_sign

European approval for Janssen’s Tremfya in active psoriatic arthritis, either alone or in combo

December 2, 2020
Research and Development, Sales and Marketing Europe, Janssen, Tremfya

The European Commission has authorised Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) in the treatment of active psoriatic arthritis (PsA), either …

News
janssen_latest_logo_on_sign

CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis

October 19, 2020
Sales and Marketing CHMP, EMA, Janssen, Tremfya

Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …

News
janssen_latest_logo_on_sign

Jannsen’s Tremfya becomes first FDA-approved IL-23 inhibitor for active psoriatic arthritis

July 15, 2020
Research and Development, Sales and Marketing FDA, Jannsen, Tremfya, active psoriatic arthritis

Janssen has reported that its therapy Tremfya (guselkumab) has become the first selective interleukin (IL)-23 inhibitor approved by the FDA …

News
janssen_latest_logo_on_sign_closer

Tremfya’s skin clearance benefit lasts up to four years in plaque psoriasis patients, Janssen says

June 15, 2020
Research and Development, Sales and Marketing Janssen, Tremfya, plaque psoriasis

Janssen has revealed new data on its interleukin (IL)-23 inhibitor Tremfya (guselkumab) at the American Academy of Dermatology (AAD) virtual …

News
janssen_latest_logo_on_sign_closer

Janssen’s Tremfya shows skin clearance benefit for psoriatic arthritis patients in two Phase 3 studies

June 4, 2020
Research and Development Janssen, Tremfya, psoriatic arthritis

Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in …

News
lilly_building_with_american_flag_web

Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

August 15, 2019
Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …

News
janssen_latest_logo_on_sign_closer

Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis

October 22, 2018
Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis

Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …

News
janssen_latest_logo_on_sign

Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis

September 13, 2018
Research and Development Humira, Janssen, Tremfya, pharma, psoriasis

Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …

News

Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis

May 11, 2018
Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis

NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

News

J&J uses FDA Priority Review Voucher to snag psoriasis approval

July 14, 2017
Medical Communications, Sales and Marketing Janssen, Johnson & Johnson, Tremfya, biotech, drugs, pharma, pharmaceutical

The FDA has handed out another approval, as the agency now easily surpasses last year’s figure of 22 already, this …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023